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Abstract 22 
In veterinary medicine, assay performance is often affected by the lack of species-specific 23 
diagnostic tools. Reliable biomarkers might be identified by investigating biological fluids of the 24 
species of interest, but protein sequence databases are often incomplete and human-specific devices 25 
for reducing sample complexity might fail when applied to animal plasma. Here, seven commercial 26 
methods, based on different capturing agents (anti-human antibodies, affinity ligands, mixture of 27 
antibodies and ligands, and combinatorial peptide ligand libraries), were applied to cat plasma and 28 
evaluated in terms of yield, identified proteins/ peptides, and relative abundance by high resolution 29 
shotgun proteomics and label-free quantitation. As a result, anti-human antibody-based methods 30 
were unsatisfactory. Most failed in reducing albumin and immunoglobulins, and some led to a 31 
substantial removal of other highly abundant proteins, probably because of nonspecific interactions. 32 
A protein A/dye ligand-based method was efficient in reducing immunoglobulins, fibrinogen and 33 
apolipoprotein A1 and A2, but not albumin, and protein identifications did not increase. Only 34 
peptide ligand libraries flattened the dynamic range, and increased protein identification (59.0%). 35 
Albumin and immunoglobulins were successfully depleted (60.7% and 35.9%, respectively). 36 
Although further studies will be required for reinforcing our observations, this work can provide a 37 
useful guide for cat plasma pretreatment in biomarker discovery studies. 38 
  39 
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Farm animal and pet welfare is the main goal of veterinary medicine for both economic and 40 
affection reasons. Nowadays, the performance of animal diagnostic serology is often sub-optimal, 41 
mostly due to the low availability of commercial species-specific immunoassays [1]. Even though 42 
clinical care may capitalize from what has already been discovered by human system biology, 43 
dedicated biomarker discovery and validation efforts would be needed for improving veterinary 44 
diagnostics [2]. Nevertheless, compared to humans, biomarker discovery studies directly performed 45 
on animal specimens lag considerably behind [3-5]. This might be partly due to specific difficulties 46 
in treating samples and to the limited availability of annotated protein sequence databases [6]. One 47 
of the main problems in proteomic analysis of biological specimens such as plasma, serum, and 48 
urine, is the presence of a huge dynamic molecular range of protein concentration [7-9]. The 49 
availability of commercial products aimed at depleting highly abundant protein and enriching the 50 
low abundant ones generally enables a more efficient and less challenging biomarker discovery 51 
process. However, most commercial solutions based on immunoaffinity criteria have been 52 
developed for human specimens, and only a limited amount of products are specific for, or 53 
compatible with some animal species [10-13]. Other products are composed by a mixture of affinity 54 
ligands (protein G or protein A, dye ligands, peptide libraries), theoretically allowing their use on a 55 
wider range of organisms [14-16]. To our knowledge, no antibody-based depletion kit has been 56 
declared by the manufacturers as suitable for feline samples, and only a limited number of papers 57 
report proteomic studies on cat biofluids [17], none of them applying procedures for 58 
depletion/enrichment of highly abundant proteins. Recently, a comparative evaluation of seven 59 
commercial products was performed by our group on a human serum sample by means of a shotgun 60 
proteomics approach [18, 19]. Here, we aimed at evaluating the same methods on a cat plasma 61 
sample to gather information on their depletion performances and to provide a selection guide for 62 
plasma biomarker discovery studies in this species.  63 
4 
 
Different capturing criteria were involved: i) immunoaffinity with antibodies directed against 64 
specific (human) proteins, ii) protein G and antibodies directed against human serum albumin 65 
(HSA), iii) protein A and cibacron blue dye-ligand, and iv) affinity for a combinatorial peptide 66 
ligand library. All products were applied to a pool of plasma samples and the enriched proteins 67 
were evaluated by SDS-PAGE, high resolution shotgun MS analysis and label-free quantitation. 68 
Plasma samples from four cats, were homogeneously pooled and stored at -80°C until use. Pool 69 
protein concentration was 63 mg/mL based on the BCA assay (Thermo Fisher Scientific, CA). 70 
Depletions and enrichments were performed according to the product manuals with the sample 71 
volumes recommended by the manufacturers [18]. Products were based on four different capturing 72 
agents: antibodies (Qproteome Albumin/IgG Depletion kit, “Qproteome”, Qiagen, Sweden; 73 
ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit, “ProteoPrep”, Sigma-Aldrich, MO; 74 
Top 2 Abundant Protein Depletion Spin Columns “Top 2”, and Top 12 Abundant Protein Depletion 75 
Spin Columns “Top 12”, Thermo Fisher Scientific), specific ligands (Albumin/IgG Removal, 76 
“CibB-A”, Thermo Fisher Scientific), mixture of antibodies and ligands (Albumin and IgG 77 
Depletion SpinTrap, “SpinTrap”, GE Healthcare, Sweden), and combinatorial peptide ligand 78 
libraries (ProteoMiner beads, “ProteoMiner”, Bio-Rad, CA), respectively. Table S1 summarizes the 79 
selected products and their relative features. Two technical replicates were performed for each 80 
procedure. A non-reducing Laemmli buffer was added to 10 µg of each depleted/enriched fraction 81 
and SDS-PAGE was carried out on any kD precast polyacrylamide gels using the Mini-Protean 82 
system (Bio-Rad). Filter aided sample preparation (FASP) was performed on all protein samples to 83 
obtain tryptic peptide mixtures; LC-MS/MS analysis was carried out on a Q Exactive mass 84 
spectrometer interfaced with an UltiMate 3000 RSLCnanoLC system (Thermo Fisher Scientific), by 85 
performing a linear gradient of 245 min from 5% to 37.5% of eluent B (0.1% formic acid in 80% 86 
acetonitrile) in eluent A (0.1% formic acid) at a flow rate of 250 nL/min. MS data were acquired 87 
using a data-dependent top12 method, as previously described [18, 21]. Proteome Discoverer 88 
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(version 1.4; Thermo Fisher Scientific) was used for protein identification with Sequest-HT as 89 
search engine. Raw files were processed with the following parameters: database Felis silvestris 90 
catus, downloaded from UniProtKB_TrEMBL (release 2017 08); enzyme trypsin, with two missed 91 
cleavages allowed; precursor mass tolerance 10 ppm; MS/MS tolerance 0.02 Da; charge states +2, 92 
+3, and +4; cysteine carbamidomethylation as static modification and methionine oxidation as 93 
dynamic modification. The percolator algorithm was used for protein significance and for peptide 94 
validation (FDR<0.01%). Uncharacterized proteins were identified by Basic Local Alignment 95 
Search Tool (BLAST) homology search. 96 
Relative protein abundance was assessed by label-free quantitation based on the spectral counting 97 
(SpC) approach, calculating the normalized spectral abundance factor (NSAF) according to Old et 98 
al. [20]. All statistical analyses were performed using t-test (p-value ≤0.05). 99 
According to the manufacturers suggestions, 10 µL of plasma were processed by Top 2, Top 12 and 100 
CibB-A columns, approximately corresponding to 0.63 mg of proteins; 25 µL of sample were 101 
incubated with SpinTrap, Qproteome and ProteoPrep columns, equivalent to 1.58 mg of proteins, 102 
and a 40 µL aliquot, accounting for 2.52 mg of proteins, was incubated with the appropriate volume 103 
of ProteoMiner beads, respecting the volume/volume ratio suggested by the manufacturer for 104 
serum/plasma samples. To evaluate protein yields for each product, the concentrations of 105 
depleted/enriched fraction were estimated. Unexpectedly, total recovery was very high in most of 106 
the applied protocols; more in detail, the protein content of recovered fractions spanned from a 107 
minimum of 31% for Top 12, to 33% for CibB-A, 35% for ProteoPrep, 39% for Top 2, up to a 108 
maximum of 48% for SpinTrap and Qproteome, when compared to the untreated plasma sample. 109 
Only ProteoMiner led to a very low yield of 1.8%, suggesting a depletion of a large amount of 110 
proteins. These yields were very different from the analogues calculated on human serum [18], 111 
revealing that both immuno- and chemical-affinity based products, except for the combinatorial 112 
peptide ligand library, have weaker interactions with cat plasma proteins.  113 
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To visualize the overall effect of each method, 10 µg aliquots of untreated plasma, of the 114 
depleted/enriched fractions and of the residual proteins were analyzed by SDS-PAGE. As shown in 115 
Figure 1, as a result of all procedures but ProteoMiner, the protein profile (red) remained very 116 
similar to the untreated sample (purple). However, a partial removal of highly abundant proteins did 117 
occur, as demonstrated by the residual protein fractions collected during each procedure (Figure 1, 118 
blue), which revealed a depletion of feline serum albumin (FSA, gel band at about 50 kDa) and 119 
immunoglobulins (Igs, gel bands from the top of the gel to about 100 kDa), even though in different 120 
amounts. After tryptic digestion, untreated plasma and depleted/enriched fractions were analyzed by 121 
a long-gradient LC-MS/MS to assess protein numbers and identities, and the relative abundance 122 
was estimated by label-free quantitation. Table 1 and Supplementary Table S2 summarize MS 123 
results. The highest number of proteins and peptides were identified after ProteoMiner enrichment, 124 
showing an increase of 59.0% and 24.9% when compared to untreated plasma, respectively. The 125 
other procedures led to a number of identified proteins quite similar to the undepleted plasma. Only 126 
CibB-A reduced the number of identified proteins and peptides, probably due to nonspecific 127 
interactions with many plasma proteins. 128 
Further, to assess the effect of treatments on most abundant proteins, their variation in comparison 129 
to the untreated sample was calculated. Considering that the sequence identity between HSA and 130 
FSA is 82.4%, it would be reasonable to expect an efficient removal of this protein with an anti-131 
HSA antibody, as reported by others for dog serum albumin (80.1% identity with HSA) [13]. 132 
Surprisingly, FSA removal was efficient only with the ProteoMiner approach, with a depletion of 133 
60.7%; FSA content was slightly reduced by Top 2, whereas its amount was even increased by all 134 
the other products. CibB-A, despite exploiting a dye ligand bait supposed not to be species-specific, 135 
provided a 2.2-fold increase in the relative FSA content (Figure 2A). Regarding Igs, all the 136 
identifications referable to Igs were considered and the overall variation was calculated (Figure 2B). 137 
The best result was obtained by CibB-A, leading to a 59.7% of total Igs decrease, suggesting that 138 
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protein A has a higher affinity to cat Igs than protein G and anti-Igs antibodies. In general, all 139 
procedures allowed only a modest removal of Igs. Interestingly, results were similar to those seen 140 
with human serum [18] on other highly abundant proteins; more in detail, upon ProteoMiner 141 
treatment, serotransferrin, α2-macroglobulin, α1-antitrypsin, haptoglobin, and α1-acid glycoprotein 142 
(Accession: M3WBQ5, M3WMA9, M3WCX1, M3W4S3, and Q6KCA0, respectively) were 143 
decreased, whereas fibrinogen α-chain and fibrinogen β-chain (Accession: M3W022, and M3WII3) 144 
were increased; likewise, CibB-A led to a considerable reduction of fibrinogen. In addition, CibB-A 145 
induced a substantial decrease of apolipoprotein A1 and A2 (Accession: M3WPG6, and M3WN87) 146 
and an increase of serotransferrin, α2-macroglobulin, α1-antitrypsin, haptoglobin, and α1-acid 147 
glycoprotein contents. The other products, apart from few variations consisting in a slight decrease 148 
of fibrinogen α-chain and fibrinogen β-chain by Top 12, an increase of α1-antitrypsin by both Top 2 149 
and Top 12, and of α1-acid glycoprotein by SpinTrap and QProteome, did not have an effect on the 150 
most abundant proteins. Further, the effect on low abundant proteins was evaluated; a total of 302 151 
proteins were identified only by ProteoMiner approach (Supplementary Table S3). Among them, 152 
many human homologous proteins have been reported to be present in ng/mL (tenascin X, [22], 153 
thrombomodulin [23] and others) to pg/mL (inhibin B, [24]) concentrations in serum samples from 154 
normal subjects. 155 
In conclusion, our data demonstrate that anti-human antibody-based methods are not suitable for cat 156 
plasma samples; on the contrary, CibB-A was very efficient in reducing Igs, fibrinogen and 157 
apolipoprotein A1 and A2; noteworthy, ProteoMiner allowed flattening of the sample dynamic 158 
range and a significant increase in the number of identified proteins. It is likely that the binding 159 
affinities of anti-human antibodies, protein G and cibacron blue dye-ligand are not adequate for cat 160 
proteins removal, even in case of high sequence identity with the homologous human protein, 161 
maybe due to a different protein domain exposure, or to the absence/presence of post-translational 162 
modifications that impairs the interactions. Otherwise, the high heterogeneity of ligands provided 163 
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by ProteoMiner beads (several millions of hexapeptide sequences) might favor the chance of 164 
establishinginteractions . Moreover, it should be underlined that all procedures, but ProteoMiner 165 
beads, provide for subsequent analysis a flow-through fraction, that may still be rich in target 166 
proteins due to their overabundance compared to the limited availability of binding sites; 167 
consequently, a fine optimization of the sample amount to be loaded should be performed before 168 
treatments. Although further studies carried out on a higher number of samples will be required to 169 
reinforce our observations, this work provides a useful guide for selecting depletion procedures in 170 
biomarker discovery studies on cat plasma. 171 
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Figure legends 220 
Figure 1. SDS-PAGE of plasma fractions with and without treatments. Protein profiles of 221 
untreated plasma (purple), depleted/enriched fractions (red) and residual proteins (blue) after Top 2, 222 
Top 12, SpinTrap, Qproteome, ProteoPrep, CibB-A, ProteoMiner. U: unbound protein fractions. E: 223 
proteins eluted from the resins. M: Precision Plus molecular weight markers (Bio-Rad). 224 
 225 
Figure 2 Abundance (NSAF) variations of serum albumin (panel A) and total 226 
immunoglobulins (panel B) after plasma treatment. Plotted values represent the average 227 
NSAF±SD. Asterisks indicate statistically significant differences between untreated and 228 
depleted/enriched plasma according to t-test, with *p value≤ 0.05 and ** p value≤ 0.01. 229 
  230 
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Table 1. Numbers of identified proteins, peptides, PSMs and Search Inputs in untreated and 231 
depleted/enriched plasma. 232 
 233 
  Proteins CV (%) Peptides CV (%) PSMs CV (%) Search Inputs CV (%) 
Plasma 390 ± 8 1.99 4245 ± 63 1.48 13112 ± 86 0.65 80323 ± 86 0.11 
CibB-A  264 ± 0** 0.00 2214 ± 30** 1.34 10455 ± 71** 0.68 70498 ± 1242** 1.76 
ProteoPrep  353 ± 13 3.61 3932 ± 52* 1.33 12608 ± 66* 0.53 81329 ± 1114 1.37 
SpinTrap  385 ± 16 4.04 4047 ± 65 1.61 13377 ± 213 1.60 78574 ± 1314 1.67 
Top 12  395 ± 7 1.79 4303 ± 24 0.56 13690 ± 74* 0.54 79571 ± 1225 1.54 
Qproteome  396 ± 6 1.61 3872 ± 69* 1.77 13488 ± 601 4.46 77057 ± 2502 3.25 
Top 2  398 ± 7 1.78 4346 ± 13 0.29 13602 ± 71* 0.52 78296 ± 44** 0.06 
ProteoMiner  620 ± 2** 0.34 5303 ± 42** 0.80 15408 ± 65** 0.42 77151 ± 619* 0.80 
Numbers represent the average from technical replicates ± SD. 234 
CV: coefficient of variation. Significant differences between untreated and depleted/enriched plasma, according to t-test, are 235 
indicated as * (p value≤0.05), or ** (p value≤0.01). 236 
 237 
